Medtronic Raised its Outlook as Heart Devices Accelerate, But Can the Momentum Last?

Medtronic, the medical device company, raised its fiscal 2027 revenue outlook after its strong performance in the past quarter. The company now expects organic revenue growth of 7.25% to 7.75%, up from its previous forecast of 6.75% to 7.25%. The improvement reflects solid demand for its cardiovascular devices, with the segment growing 19.5% to $3.93 billion.

Medtronic's pulsed field ablation portfolio, used to treat irregular heart rhythms, saw an 88% surge. The company is also investing in heart-valve technology and surgical robotics to bolster its longer-term growth portfolio. CEO Geoff Martha highlighted that the outlook is not based solely on one established product category, but rather a growing contribution from newer platforms.

Medtronic is also expanding into heart-valve repair device company Pi-Cardia and will receive an option to acquire it for $210 million. Additionally, the company invested $700 million in Cornerstone Robotics and will distribute the Sentire robotic surgical system in certain markets outside the United States. However, sustaining the recent growth momentum will be crucial, as tariffs and execution risks remain uncertainties.